Enterprise Value

-29.2M

Cash

48.38M

Avg Qtr Burn

N/A

Short % of Float

2.58%

Insider Ownership

31.89%

Institutional Own.

31.46%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

Phase 3

Interim Update

EQ101 Details
Celiac disease, Alopecia areata

Phase 2

Data readout

EQ001 (Itolizumab) Details
Ulcerative colitis

Phase 2

Update

Phase 1b

Data readout

Phase 1b

Update

EQ102 Details
Celiac disease

Phase 1

Data readout